ADIM (4142) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 國光生

ADIM (4142) reported revenue of NT$634 million for Oct 2026, +6.7% year on year and +104.8% from the previous month. Revenue for Jan–Oct 2026 was NT$1.5 billion (+19.9% year on year).

Revenue for Oct 2026 was a record high (previous high: Oct 2025, NT$594 million). →

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 13 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$480 million24/10Nov 2024 NT$20.5 millionDec 2024 NT$44.6 millionJan 2025 NT$61.8 millionFeb 2025 NT$7.3 million25/02Mar 2025 NT$3 millionApr 2025 NT$4 millionMay 2025 NT$4.5 millionJun 2025 NT$100.2 million25/06Jul 2025 NT$239.7 millionAug 2025 NT$72.8 millionSep 2025 NT$162.8 millionOct 2025 NT$594 million25/10Nov 2025 NT$130.8 millionDec 2025 NT$20.6 millionJan 2026 NT$11 millionFeb 2026 NT$5.8 million26/02Mar 2026 NT$65.5 millionApr 2026 NT$22.7 millionMay 2026 NT$6.8 millionJun 2026 NT$37.2 million26/06Jul 2026 NT$308.2 millionAug 2026 NT$97.9 millionSep 2026 NT$309.5 millionOct 2026 NT$634 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$634 million+6.7%+104.8%
Sep 2026NT$309.5 million+90.1%+216.1%
Aug 2026NT$97.9 million+34.5%-68.2%
Jul 2026NT$308.2 million+28.6%+727.7%
Jun 2026NT$37.2 million-62.8%+449.7%
May 2026NT$6.8 million+51.9%-70.2%
Apr 2026NT$22.7 million+474.4%-65.3%
Mar 2026NT$65.5 million+2,102.7%+1,019.6%
Feb 2026NT$5.8 million-19.7%-46.7%
Jan 2026NT$11 million-82.2%-46.7%
Dec 2025NT$20.6 million-53.8%-84.3%
Nov 2025NT$130.8 million+537.9%-78.0%
Oct 2025NT$594 million+23.8%+264.9%
Sep 2025NT$162.8 million-52.3%+123.6%
Aug 2025NT$72.8 million-60.9%-69.6%
Jul 2025NT$239.7 million-33.6%+139.2%
Jun 2025NT$100.2 million+39.6%+2,146.5%
May 2025NT$4.5 million+223.0%+12.6%
Apr 2025NT$4 million-40.6%+33.2%
Mar 2025NT$3 million-91.1%-59.2%
Feb 2025NT$7.3 million-2.8%-88.2%
Jan 2025NT$61.8 million+1,972.7%+38.8%
Dec 2024NT$44.6 million—+117.2%
Nov 2024NT$20.5 million-86.7%-95.7%
Oct 2024NT$480 million-4.1%+40.8%

Jan–Oct 2026 cumulative: NT$1.5 billion (+19.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: ADIM vs PEC / ADIM vs Lotus Pharm / ADIM vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16